Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation
Abstract
The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.
Conditions: Alzheimer Disease.
Primary outcome: The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595; The percentage of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595.
Enrollment: 20 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Diarylethenes for Memories and Switches
- Long-Term Potentiation and Memory
- Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices
- The Cognitive Neuroscience of Working Memory
- Memory aging and brain maintenance
- Effector and Memory CTL Differentiation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.